{"id":"W2101440707","doi":"10.1016/j.cllc.2015.05.010","title":"A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"ca_institutions":"Boehringer Ingelheim (Canada); Regional Municipality of Durham; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Ottawa Hospital; McGill University Health Centre; Juravinski Cancer Centre","funders":"","keywords":"Pemetrexed; Medicine; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Adverse effect; Hazard ratio; Chemotherapy; Randomized controlled trial; Confidence interval; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009513784,0.0004040938,0.001988786,0.0002514771,0.00008101853,0.00004678472,0.0001478185,0.0001555217,0.0001289911],"category_scores_gemma":[0.00009110441,0.0002640594,0.0001248671,0.0004665224,0.000201687,0.0001880686,0.00003196999,0.000197211,3.067788e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001185615,"about_ca_system_score_gemma":0.002327751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003548024,"about_ca_topic_score_gemma":0.01267785,"domain_scores_codex":[0.9972593,0.0002185924,0.001170893,0.0006734213,0.0003170641,0.0003606853],"domain_scores_gemma":[0.9976923,0.0006378703,0.0005683383,0.0003728335,0.0004272081,0.000301435],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9455742,0.01134051,0.0254627,0.0001543934,0.001463787,0.00002063745,0.002654409,0.0001987275,0.0001183416,0.00002140322,0.0005262179,0.01246466],"study_design_scores_gemma":[0.9473722,0.02637018,0.0007229449,0.0006465221,0.001466912,0.000001836864,0.0002948113,0.02092449,0.0009861811,0.00006112944,0.0008544787,0.0002983111],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9787045,0.004274023,0.0005256634,0.001365905,0.0003009709,0.01422191,0.000279909,0.00002482374,0.0003022704],"genre_scores_gemma":[0.9850707,0.002303106,0.002792266,0.0005311354,0.0001531271,0.00653485,0.0001636237,0.00008372777,0.002367438],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02473976,"threshold_uncertainty_score":0.9999812,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08825096488267198,"score_gpt":0.4698113163662173,"score_spread":0.3815603514835453,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}